Advanced Biomed Launches A+PerfusC System Designed To Replicate Human Physiological Conditions In Vitro

Author: Benzinga Newsdesk | September 19, 2025 08:34am

Advanced Biomed Inc. (NASDAQ:ADVB) (the "Company", "Advanced Biomed"), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced the launch of its A+PerfusC™ system, a compact, all‑in‑one perfusion 3D cell culture incubator designed to replicate human physiological conditions in vitro.

The A+PerfusC™ platform integrates automated perfusion with environmental control in a compact format that can be mounted directly onto a microscope for real‑time observation. The system supports up to 12 days of continuous, hands‑free culture, reducing the risk of human error and contamination. By maintaining uniform nutrient delivery and preventing waste accumulation, the platform promotes spheroid and organoid formation, enhancing cell viability, growth, and drug response predictability. The system is characterized and proved by:

• 8 independent channel/patient source per plate
• 600 tumor spheroids per row for one patient
• 4,800 tumor spheroids per plate
• Easy to transfer into 96 or 384 well plate for high-throughput drug screening
• Easy to mount on microscopy platforms
• Expandable- control platform supporting up to four incubators. (undergoing)

Posted In: ADVB